dc.contributorSaavedra Salinas, M.A., Departamento de Reumatolog�a, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, UNAM, M�xico, Distrito Federal, M�xico; Barrera Cruz, A., Divisi�n de Excelencia Cl�nica, �rea de Desarrollo de Gu�as de Pr�ctica Cl�nica, IMSS, M�xico, Distrito Federal, M�xico; Cabral Casta�eda, A.R., Ciencias M�dicas F, Departamento de Inmunolog�a y Reumatolog�a, Instituto Nacional de Ciencias M�dicas y Nutrici�n Salvador Zubir�n, M�xico, Distrito Federal, M�xico; Jara Quezada, L.J., Direcci�n de Educaci�n e Investigaci�n, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, UNAM, M�xico, Distrito Federal, M�xico; Arce-Salinas, C.A., Divisi�n de Medicina Interna, Hospital Central Sur de Pemex, M�xico, Distrito Federal, M�xico; �lvarez Nemegyei, J., Escuela de Medicina, Universidad An�huac-Mayab, M�rida, Yucat�n, M�xico; Fraga Mouret, A., Direcci�n de Educaci�n e Investigaci�n, Secretar�a de Salud del Distrito Federal, UNAM, M�xico, Distrito Federal, M�xico; Orozco Alcal�, J., Cl�nica de Reumatolog�a, Escuela de Medicina, Universidad de Guadalajara. Guadalajara, Jalisco, M�xico; Salazar P�ramo, M., Divisi�n de Investigaci�n en Salud, UMAE, Hospital de Especialidades, Centro M�dico Nacional de Occidente, IMSS, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara. Guadalajara, Jalisco, M�xico; Cruz Reyes, C.V., Departamento de Reumatolog�a, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, M�xico, Distrito Federal, M�xico; Andrade Ortega, L., Departamento de Reumatolog�a, Centro M�dico Nacional 20 de Noviembre, ISSSTE. UNAM, M�xico, Distrito Federal, M�xico; Vera Lastra, O.L., Departamento de Medicina Interna, Hospital de Especialidades, CMN La Raza, IMSS, UNAM, M�xico, Distrito Federal, M�xico; Mendoza Pinto, C., Unidad de Investigaci�n Enfermedades Autoinmunes Sist�micas, Hospital General Regional No. 36-CIBIOR, Instituto Mexicano del Seguro Social. Unidad de Posgrado, Facultad de Medicina, Benem�rita Universidad Aut�noma de Puebla, Puebla, Puebla, M�xico; S�nchez Gonz�lez, A., Departamento de Reumatolog�a, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, IMSS, M�xico, Distrito Federal, M�xico; Cruz Cruz, P.D.R., Divisi�n de Atenci�n Ginecoobst�trica y Perinatal de la Direcci�n de Prestaciones M�dicas del IMSS, M�xico, Distrito Federal, M�xico; Morales Hern�ndez, S., Departamento de Perinatolog�a, Hospital Gineco-Obstetricia No. 3 Dr. V�ctor Manuel Espinosa de los Reyes S�nchez. UMAE, CMN La Raza, M�xico, Distrito Federal, M�xico; Portela Hern�ndez, M., Departamento de Reumatolog�a, Hospital de Especialidades, CMN Siglo XXI, IMSS, M�xico, Distrito Federal, M�xico; P�rez Crist�bal, M., Departamento de Reumatolog�a, Hospital de Especialidades, CMN Siglo XXI, IMSS, M�xico, Distrito Federal, M�xico; Medina Garc�a, G., Hospital de Especialidades, CMN La Raza, IMSS, M�xico, Distrito Federal, M�xico; Hern�ndez Romero, N., Unidad de Cuidados Intensivos Neonatales. Hospital Gineco-Obstetricia No. 3 Dr. V�ctor Manuel Espinosa de los Reyes S�nchez. UMAE, CMN La Raza, M�xico, Distrito Federal, M�xico; Velarde Ochoa, M.D.C., Departamento de Reumatolog�a e Inmunolog�a Cl�nica, Hospital General de Zona No. 46, IMSS, Villahermosa, Tabasco, M�xico; Navarro Zarza, J.E., Hospital General de Chilpancingo Dr. Raymundo Abarca Alarc�n, Chilpancingo, Guerrero, M�xico; Portillo D�az, V., Departamento de Medicina Interna, UMAE HGO 4, IMSS, M�xico, Distrito Federal, M�xico; Vargas Guerrero, A., Departamento de Reumatolog�a, Instituto Nacional de Cardiolog�a Ignacio Ch�vez, M�xico, Distrito Federal, M�xico; Goycochea Robles, M.V., Unidad de Investigaci�n en Epidemiolog�a Cl�nica, Hospital Regional Dr. Carlos Mcgregor S�nchez Navarro, IMSS, M�xico, Distrito Federal, M�xico; Garc�a Figueroa, J.L., Universidad Ju�rez Aut�noma de Tabasco, Villahermosa, Tabasco, M�xico; Barreira Mercado, E., Reumatolog�a, Facultad de Medicina, Universidad Aut�noma de Quer�taro y Universidad del Valle de M�xico. Quer�taro, Qro., M�xico; Amigo Casta�eda, M.C., Reumatolog�a, Centro M�dico ABC, M�xico, Distrito Federal, M�xico
dc.creatorSaavedra Salinas, M.A.
dc.creatorBarrera Cruz, A.
dc.creatorCabral Castaneda, A.R.
dc.creatorJara Quezada, L.J.
dc.creatorArce-Salinas, C.A.
dc.creatorAlvarez Nemegyei, J.
dc.creatorFraga Mouret, A.
dc.creatorOrozco Alcala, J.
dc.creatorSalazar Paramo, M.
dc.creatorCruz Reyes, C.V.
dc.creatorAndrade Ortega, L.
dc.creatorVera Lastra, O.L.
dc.creatorMendoza Pinto, C.
dc.creatorSanchez Gonzalez, A.
dc.creatorCruz Cruz, P.D.R.
dc.creatorMorales Hernandez, S.
dc.creatorPortela Hernandez, M.
dc.creatorPerez Cristobal, M.
dc.creatorMedina Garcia, G.
dc.creatorHernandez Romero, N.
dc.creatorVelarde Ochoa, M.D.C.
dc.creatorNavarro Zarza, J.E.
dc.creatorPortillo Diaz, V.
dc.creatorVargas Guerrero, A.
dc.creatorGoycochea Robles, M.V.
dc.creatorGarcia Figueroa, J.L.
dc.creatorBarreira Mercado, E.
dc.creatorAmigo Castaneda, M.C.
dc.date.accessioned2015-09-15T17:32:27Z
dc.date.accessioned2022-11-02T14:34:31Z
dc.date.available2015-09-15T17:32:27Z
dc.date.available2022-11-02T14:34:31Z
dc.date.created2015-09-15T17:32:27Z
dc.date.issued2015
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84922750479&partnerID=40&md5=4563b3e5b406a3fb13192ae227356be8
dc.identifierhttp://hdl.handle.net/20.500.12104/40125
dc.identifier10.1016/j.reuma.2014.12.004
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5000671
dc.description.abstractBackground: Pregnancy in women with autoimmune rheumatic diseases is associated with several maternal and fetal complications. The development of clinical practice guidelines with the best available scientific evidence may help standardize the care of these patients. Objectives: To provide recommendations regarding prenatal care, treatment, and a more effective monitoring of pregnancy in women with lupus erythematosus, rheumatoid arthritis (RA) and antiphospholipid syndrome (APS). Methodology: Nominal panels were formed for consensus, systematic search of information, development of clinical questions, processing and staging of recommendations, internal validation by peers and external validation of the final document. The quality criteria of the AGREE II instrument were followed. Results: The panels answered 37 questions related to maternal and fetal care in lupus erythematosus, RA and APS, as well as for use of antirheumatic drugs during pregnancy and lactation. The recommendations were discussed and integrated into a final manuscript. Finally, the corresponding algorithms were developed. In this second part, the recommendations for pregnant women with RA, APS and the use of antirheumatic drugs during pregnancy and lactation are presented. Conclusions: We believe that the Mexican clinical practice guidelines for the management of pregnancy in women with RA and APS integrate the best available evidence for the treatment and follow-up of patients with these conditions. � 2014 Elsevier Espa�a, S.L.U.
dc.relationScopus
dc.relationReumatologia Clinica
dc.titleClinical practice guidelines for the attention of pregnant women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II
dc.typeArticle in Press


Este ítem pertenece a la siguiente institución